Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panzem NCD + Temozolomide in Recurrent Glioblastoma Multiforme
NCT00481455Phase 2Completed
- Sponsor
- CASI Pharmaceuticals, Inc.
- Start
- Apr 2007
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Panzem in glioblastoma multiforme (GBM), sponsored by CASI Pharmaceuticals, Inc. Primary endpoints: Progression-Free Survival at 6 months and Overall Survival. Started Apr 2007; status: completed.
02
Drugs
Panzem
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00481455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00481455.